Urinary incontinence induced by the antidepressants – case report

Česká verzia

Authors: J. Krhut ^1,2; M. Gärtner ³
Authors place of work: Urologické oddělení FN, Ostrava, primář doc. MUDr. J. Krhut, Ph. D. ¹; Katedra chirurgických oborů LF OU, Ostrava, přednosta doc. MUDr. P. Zonča, Ph. D., FRCS ²; Gynekologicko-porodnická klinika FN, Ostrava, přednosta doc. MUDr. V. Unzeitig, CSc. ³
Published in the journal: Ceska Gynekol 2015; 80(1): 65-68

Summary

Aim:
Case study of the patient with urinary incontinence induced by the antidepressant mirtazapin and the review of the related literature.

Design:
Case report.

Setting:
Department of Urology, University Hospital Ostrava-Poruba.

Case report:
A case of 55-years old patiens, who was reffered to the surgical treatment of the urinary incontinence. We found a major discrepancies during the evaluation that led us to suspect that this is not a common uncomplicated case of stress urinary incontinence. Based on the detailed history we identified the antidepressant mirtazapine as a likely causal factor. After discontinuing mirtazapin patient has achieved full control of the continence.

Conclusion:
Given that antidepressants affects adrenergic and dopaminergic regulatory mechanisms in the central nervous system, they may affect the lower urinary tract function. This work presents a case report where the disclosure of the less common cause of incontinence saved the patientoriginally proposed surgical treatment and allowed the effective restoration of the continence. We emphasize the need to consider the potential interaction of antidepressants with lower urinary tract function in daily practice.

Keywords:
urinary incontinence, antidepressants, serotonin, noradrenalin, mirtazapine

Zdroje

1. Abrams, P., Cardozo, L., Fall, M., et al. Standardisation sub-committee of the International Continence Society: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology, 2003, 61, 1, p. 37–49.

2. Blackett, H., Walker, R., Wood, B. Urinary dysfunction in Parkinson´s disease: a review. Parkinsonism Relat Disord, 2009, 15, 2, p. 81–87.

3. Drake, MJ., Nixon, PM., Crew, JP. Drug-induced bladder and urinary disorders. Drug Safety, 1998, 19, 1, p. 45–55.

4. Hall, SA., Maserejian, NN., Link, CL., et al. Are commonly used psychoactive medications associated with lower urinary tract symptoms? Eur J Clin Pharmacol, 2012, 68, 5, p. 783–791.

5. Hannestad, YS., Rortveit, G., Sandvik, H., Hunskaar, S. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol, 2000, 53, 11, p. 1150–1157.

6. Kent, JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet, 2000, 355, p. 911–918.

7. Kessler, RC., Berglund, P., Demler, O. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA, 2003, 289, 203, p. 3095–3105.

8. Mariappan, P., Alhasso, A., Ballantyne, Z., et al. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol, 2007, 51, 1, p. 67–74.

9. Milsom, I., Kaplan, SA., Coyne, KS., et al. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology, 2012, 80, 1, p. 90–96.

10. Movig, KLL., Leufkens, HGM., Belitser, SV., et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf, 2002, 11, 4, p. 271–279.

11. Seventh report on the standardisation of terminology of lower urinary tract function: lower urinary tract rehabilitation techniques. International Continence Society Committee on Standardisation of Terminology. Scand J Urol Nephrol, 1992, 26, p. 99.